Use of human iPSCs and kidney organoids to develop a cysteamine/mTOR inhibition combination therapy to treat cystinosis
J. A. Hollywood, A. Przepiorski, P. T. Harrison, E. J. Wolvetang, A. J. Davidson, T. M. Holm
This study uses human iPSCs and kidney organoids to show that combining cysteamine and mTOR inhibition improves cystinosis treatment by correcting multiple disease phenotypes.
bioRxiv · Apr 1, 2019Pathology